Clinical Trials Directory

Trials / Unknown

UnknownNCT02621359

A Two Week Nitazoxanidebased Quadruple Regimen

A Two Week Nitazoxanidebased Quadruple Regimen for Helicobacter Pylori Therapy After Failure of Standard Triple Therapy: A Single Center Experience

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Tanta University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Helicobacter pylori (H. pylori) infection is a global health problem as it is associated with peptic ulcers, chronic gastritis, duodenitis, and stomach cancer. Therefore, the eradication of the pathogen is of critical importance to reduce H. pylori-related complications . However, due to increasing antibiotic resistance, eradication of Helicobacter pylori has become more challenging. With a great decline in the eradication rate of standard triple therapy for Helicobacter pylori to below 70% in many countries. Treatment with triple therapy, which is the most frequently recommended, fails to eradicate H. pylori in approximately 20% of cases .

Detailed description

Designing a new rescue regimen that achieves greater than 85% eradication rate is an important target of current research. Unfortunately, the most frequently used "rescue" or "salvage" therapy is bismuth quadruple therapy consisting of a proton pump inhibitor (PPI), tetracycline, metronidazole, and bismuth \[11\]. This rescue therapy is inexpensive, and relatively effective with average eradication rate of 70% when used as second-line therapy. However, disadvantages of bismuth based quadruple therapy include the large daily number of pills (sometimes exceeding 18 pills), increased dosing frequency (four times daily), and frequent side effects.

Conditions

Interventions

TypeNameDescription
DRUGNitazoxanideNitazoxanide 500 mg twice daily
DRUGLevofloxacinLevofloxacin 500 mg once daily
DRUGDoxycyclinDoxycyclin 100 mg twice daily
DRUGOmeprazoleOmeprazole 40 mg twice daily

Timeline

Start date
2015-01-01
Primary completion
2022-12-01
Completion
2022-12-01
First posted
2015-12-03
Last updated
2018-01-03

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT02621359. Inclusion in this directory is not an endorsement.